Law Firm Investigates Drugs Made In America Acquisition Corp. Merger
Monteverde & Associates PC announced an investigation into the merger between Drugs Made In America Acquisition Corp. (NASDAQ: DMAA) and Power Analytics Global Corp., examining potential shareholder concerns.
New York, NY – July 21, 2026 – The law firm Monteverde & Associates PC, specializing in class action lawsuits, has initiated an investigation into the merger agreement between Drugs Made In America Acquisition Corp. (NASDAQ: DMAA) and Power Analytics Global Corp.
The firm, led by Juan Monteverde, which has a track record of recovering funds for shareholders, is seeking to determine if the proposed transaction is fair to DMAA's stockholders. The investigation will scrutinize the terms of the deal and the conduct of the company's board and management.
Monteverde & Associates PC stated that the inquiry aims to uncover potential inaccuracies or omissions in the company's public disclosures related to the merger. Shareholders who hold common stock in Drugs Made In America Acquisition Corp. and have concerns are encouraged to contact the firm for further information.
The firm, based in New York City, has been recognized for its work in securities litigation and has previously achieved significant recoveries for investors in class action cases.